RT Journal Article
SR Electronic
T1 Delineating the heterogeneity of preimplantation development via unsupervised clustering of embryo candidates for transfer using automated, accurate and standardized morphokinetic annotation
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.03.29.22273137
DO 10.1101/2022.03.29.22273137
A1 Nir Zabari
A1 Yoav Kan-Tor
A1 Yuval Or
A1 Zeev Shoham
A1 Yoel Shofaro
A1 Dganit Richter
A1 Iris Har-Vardi
A1 Assaf Ben-Meir
A1 Naama Srebnik
A1 Amnon Buxboim
YR 2022
UL http://medrxiv.org/content/early/2022/04/02/2022.03.29.22273137.abstract
AB The majority of human embryos, whether naturally or in vitro fertilized (IVF), do not poses the capacity to implant within the uterus and reach live birth. Hence, selecting the embryos with the highest developmental potential to implant is imperative for improving pregnancy rates without prolonging time to pregnancy. The developmental potential of embryos can be assessed based on temporal profiling of the discrete morphokinetic events of preimplantation development. However, manual morphokinetic annotation introduces intra- and inter-observer variation and is time-consuming. Using a large clinically-labeled multicenter dataset of video recordings of preimplantation embryo development by time-lapse incubators, we trained a convolutional neural network and developed a classifier that performs fully automated, robust, and standardized annotation of the morphokinetic events with R-square 0.994 accuracy. To delineate the morphokinetic heterogeneity of preimplantation development, we performed unsupervised clustering of high-quality embryo candidates for transfer, which was independent of maternal age and blastulation rate. Retrospective comparative analysis of transfer versus implantation rates reveals differences between embryo clusters that are distinctively marked by poor synchronization of the third meiotic cell-cleavage cycle. We expect this work to advance the integration of morphokinetic-based decision support tools in IVF treatments and deepen our understanding of preimplantation heterogeneity.Competing Interest StatementN.Z., N.S., Y.O., Z.S., Y.S., D.R., and A.B. declare no financial or non-financial competing or other conflict of interest. I.H.V. and A.B.M. declare having no conflict of interest during the time of scientific collaboration and data collection that are relevant to this work. Since January 2020 A.B.M. serve as CTO and Chief Medical Officer, respectively and since March 2020 I.H.V. serves as the Scientific Director of Fairtility LTD, which is a company that incorporates AI into different stages in fertility treatment. Y.K.T. declares no financial or non-financial competing or other conflict of interest. Since September 2021, Y.K.T. discloses being employed by IBM-Research.Funding StatementA.B. greatly appreciates support from the European Research Council – Proof of Concept Grant (PoC 966830) and the European Research Council Grant (ERC-StG 678977). The funders did not play any role in Study design, Data collection and analysis, Decision to publish, or Preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.Not ApplicableThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This research was approved by the Investigation Review Boards of the data-providing medical centers: Hadassah Hebrew University Medical center IRB number HMO 558-14 Kaplan Medical Center IRB 0040-16-KMC Soroka Medical Center IRB 0328-17-SOR Rabin Medical Center IRB 0767-15-RMC.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.Not ApplicableI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Not ApplicableI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Not ApplicableThe copyrights of the code are owned by Yissum?the technology transfer company of The Hebrew University of Jerusalem. Requests can be sent to A.B. The clinical data are owned by Hadassah Medical Center and by Clalit Health Services. Restrictions apply to the availability of these data, which were used anonymously under ethical agreements with each clinic separately for this study, and so are not made publically available. Access requests can be directed to A.B.M. (Hadassah Medical Center), Y.O. (Kaplan Medical Center), I.H.V (Soroka University Medical Center), Y.S. (Women's Hospital, Rabin Medical Center).